Long-term efficacy of immune checkpoint inhibitors in advanced NSCLC: challenges and opportunities—a commentary of the 3-year follow-up of the KEYNOTE-001 trial
Sign Up to like & getrecommendations! Published in 2019 at "Translational cancer research"
DOI: 10.21037/tcr.2019.06.24
Abstract: Treatment of advanced non-small cell lung cancer (NSCLC) has evolved considerably over the past two decades, with improved survival outcomes in a significant proportion of patients due to the development of new effective systemic therapies.… read more here.
Keywords: immune checkpoint; term efficacy; inhibitors advanced; checkpoint inhibitors ... See more keywords
Efficacy of PD-1/PD-L1 inhibitors in advanced gastroesophageal cancer based on characteristics: a meta-analysis.
Sign Up to like & getrecommendations! Published in 2023 at "Immunotherapy"
DOI: 10.2217/imt-2022-0305
Abstract: Objective: Evaluate the potency of anti-PD-1/PD-L1 antibodies in advanced gastroesophageal cancer patients with different clinical features. Methods: Randomized, controlled trials comparing anti-PD-1/PD-L1 antibodies with chemotherapy in individuals with gastroesophageal cancer were retrieved. Results: 15Â trials involving… read more here.
Keywords: gastroesophageal cancer; efficacy inhibitors; inhibitors advanced; analysis ... See more keywords
A Contemporary Review of Immune Checkpoint Inhibitors in Advanced Clear Cell Renal Cell Carcinoma
Sign Up to like & getrecommendations! Published in 2021 at "Vaccines"
DOI: 10.3390/vaccines9080919
Abstract: The use of checkpoint inhibitors in advanced and metastatic renal cell carcinomas (RCCs) has rapidly evolved over the past several years. While immune-oncology (IO) drug therapy has been successful at resulting in improved responses and… read more here.
Keywords: immune checkpoint; renal cell; inhibitors advanced; checkpoint inhibitors ... See more keywords
Integrating PARP Inhibitors Into Advanced Prostate Cancer Therapeutics.
Sign Up to like & getrecommendations! Published in 2021 at "Oncology"
DOI: 10.46883/onc.2021.3503.0119
Abstract: DNA-damage repair (DDR) pathway mutations can sensitize cancer cells to a class of cancer therapeutics known as PARP inhibitors. Given that DDR alterations can be found in up to one-third of advanced prostate cancers, PARP… read more here.
Keywords: advanced prostate; cancer therapeutics; cancer; parp inhibitors ... See more keywords